SLC5A2 and type 2 diabetes mellitus: While dedicated cognitive endpoint trials are ongoing, current evidence positions SGLT2 inhibitors as promising dual-purpose agents for both glycemic control and potential cerebrovascular protection in T2D, though their precise neurocognitive effects require further validation through randomized controlled trials with comprehensive cognitive assessments.